#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Fixed dose combination of rosuvastatin and ezetimibe – drug profile


Authors: O. Kyselák 1;  V. Soška 1,2
Authors‘ workplace: Oddělení klinické bio­chemie, FN u sv. Anny v Brně 2 II. interní klinika LF MU, Brno 1
Published in: Kardiol Rev Int Med 2018, 20(2): 142-146

Overview

Hypercholesterolemia is the major risk factor for atherosclerotic cardiovascular diseases (ASCVD), particularly myocardial infarction. Statins are essential drugs for treatment of patients with hypercholesterolemia, but in monotherapy they are usually not effective enough to achieve the target values of LDL cholesterol. Therefore it is recommended to combine statins with ezetimibe. This combination has proven good safety and efficiency. In addition, a fixed dose combination increases patient adherence to long-term treatment.

Key words:

rosuvastatin – ezetimibe – LDL-cholesterol – cardiovascular diseases


Sources

1. Baigent C, Blackwell L, Emberson J et al. Ef­ficacy and safety of more intensive lower­­ing of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;  376(9753): 1670– 1681. doi: 10.1016/ S0140-6736(10)61350-5.

2. Mihaylova B, Emberson J, Blackwell L et al. The ef­fects of lower­­ing LDL cholesterol with statin ther­apy in people at low risk of vascular dis­ease: meta-analysis of individual data from 27 random­ised trials. Lancet 2012; 380(9841): 581– 590. doi: 10.1016/ S0140-6736(12)60367-5.

3. Catapano AL, Graham I, De Backer G et al. 2016 ESC/ EAS Guidelines for the management of dyslipidaemias. the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Atherosclerosis 2016; 253: 281– 344. doi: 10.1016/ j.atherosclerosis.2016.08.018

4. Wiegman A, Gidd­­ing SS, Watts, GF et al. Familial hypercholesterolaemia in children and adolescents: gain­­ing decades of life by optimiz­­ing detection and treatment. Eur Heart J 2015; 36(36): 2425– 2437. doi: 10.1093/ eurheartj/ ehv157.

5. Rosuvastatin. Pubchem diabase. Available at: https:/ / pubchem.ncbi.nlm.nih.gov/ compound/ Ro-suvastatin#section=Top.

6. Duriez P. Mechanisms of actions of statins and fibrates. Therapie 2003; 58(1): 5– 14.

7. Cur­rent Medication Information for Crestor. Rosuvastatin Calcium Tablet, Film-Coated. NIH, U.S. National Library of Medicine. DailyMed. Updated: May 2016. Available at: https:/ / dailymed.nlm.nih.gov/ dailymed/ drugInfo.cfm?setid=bb0f3b5e-4bc6-41c9-66b9-6257e2513512.

8. Rosuvastatin (SPC). Souhrn informací o přípravku. Dostupný na: www.sukl.cz.

9. Drug Information 2016. Bethesda: American Society of Health-System Pharmacists 2016: 1865– 1866.

10. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92(2): 152– 160.

11. Lund TM, Torsvik H, Falch D et al. Ef­fect of morn­­ing versus even­­ing intake of simvastatin on the serum cholesterol level in patients with coronary artery dis­ease. Am J Cardiol 2002; 90(7): 784– 786.

12. Athyros VG, Alexandrides TK, Bilianou H et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver dis­ease/ non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17– 32. doi: 10.1016/ j.metabol.2017.02.014.

13. Stroes ES, Thompson PD, Corsini A et al. Statin--as­sociated muscle symp­toms: impact on statin ther­apy-European Atherosclerosis Society Consensus Panel Statement on As­ses­sment, Aetiology and Man­agement. Eur Heart J 2015; 36(17): 1012– 1022. doi: 10.1093/ eurheartj/ ehv043.

14. Gupta A, Thompson D, Whitehouse A et al. ASCOT Investigators. Adverse events as­sociated with unblinded, but not with blinded, statin ther­apy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lower­­ing Arm (ASCOT-LLA): a randomised double-blind placebo-control­led trial and its non-randomised non-blind extension phase. Lancet 2017; 389(10088): 2473– 2481. doi: 10.1016/ S0140-6736(17)31075-9.

15. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97(8A): 52C– 60C.

16. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular dis­ease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Dis­ease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Euro Heart J 2016;  37(29): 2315– 2381. doi: 10.1093/ eurheartj/ ehw106.

17. Sattar N, Preiss D, Mur­ray HM et al. Statins and risk of incident diabetes: a col­laborative meta-analysis of randomised statin trials. Lancet 2010;  375(9716): 735– 742. doi: 10.1016/ S0140-6736(09)61965-6.

18. Ridker PM, Pradhan A, MacFadyen JG et al. Cardiovascular benefits and diabetes risks of statin ther­apy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380(9841): 565– 571. doi: 10.1016/ S0140-6736(12)61190-8.

19. Knopp RH, Gitter H, Truitt T et al. Ezetimibe reduces low-density lipoprotein cholesterol: results of a Phase III, randomized, double-blind, placebo--control­led trial (abstr). Atherosclerosis 2001; 2(2): 38. doi: 10.1016/ S1567-5688(01)80027-1.

20. Gagné C, Bays HE, Weiss SR et al. Ezetimibe Study Group. Ef­ficacy and safety of ezetimibe added to ongo­­ing statin ther­apy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;  90(10): 1084– 1091.

21. Ge L, Wang J, Qi W et al. The cholesterol absorption inhibitor ezetimibe acts by block­­ing the sterol-induced internalization of  NPC1L1. Cell Metab 2008; 7(6): 508– 519. doi: 10.1016/ j.cmet.2008.04.001.

22. Kishimoto M, Sugiyama T, Osame K et al. Ef­ficacy of ezetimibe as monother­apy or combination ther­apy in hypercholesterolemic patients with and with­out diabetes. J Med Invest 2011; 58(1– 2): 86– 94.

23. Ezetímib. Pubchem diabase. Available at: https:/ / pubchem.ncbi.nlm.nih.gov/ compound/ Ezetimibe#section=Top.

24. Ezetimib (SPC). Souhrn informací o přípravku. Dostupný na: www.sukl.cz .

25. Can­non CP, Blaz­­ing MA, Giugliano RP et al. Ezetimibe added to statin ther­apy after acute coronary syndromes. N Engl J Med 2015; 372(25): 2387– 2397. doi: 10.1056/ NEJMoa1410489.

26. Baigent C, Landray MJ, Reith C et tal. The ef­fects of lower­­ing LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney dis­ease (Study of Heart and Renal Protection): a random­ised placebo-control­led trial. Lancet 2011; 377(9784): 2181– 2192. doi: 10.1016/ S0140-6736(11)60739-3.

27. Giugliano RP, Can­non CP, Blaz­­ing MA et al. Benefit of add­­ing ezetimibe to statin ther­apy on cardiovascular outcomes and safety in patients with versus without diabetes mel­litus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Ef­ficacy International Trial). Circulation 2018; 137(15): 1571– 1582. doi: 10.1161/ CIRCU­-LATIONAHA.117.030950.

28. Kosoglou T, Statkevich P, Yang B et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004; 20(8): 1185– 1195. doi: 10.1185/ 030079904125004213.

29. Hong SJ, Jeong HS, Ahn, JC et al. A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the ef­ficacy and safety of combination ther­apy with ezetimibe and rosuvastatin versus rosuvastatin monother­apy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) random­ized control­led trial. Clin Ther 2018; 40(2): 226– 241. doi: 10.1016/ j.clinthera.2017.12.018.

30. Kim KJ, Kim SH, Yoon YW et al. Ef­fect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther 2016; 34(5): 371– 382. doi: 10.1111/ 1755-5922.12213.

31. Masuda J, Tanigawa T, Yamada T et al. Ef­fect of combination ther­apy of ezetimibe and rosuvastatin on regres­sion of coronary atherosclerosis in patients with coronary artery dis­ease. Int Heart J 2015; 56(3): 278– 285. doi: 10.1536/ ihj.14-311.

32. Kang WY, Seong SJ, Ohk B et al. Pharmacokinetics and bio­equivalence of a rosuvastatin/ ezetimibe fixed-dose combination tablet versus single agents in healthy male subjects. Int J Clin Pharmacol Ther 2018; 56(1): 43– 52. doi: 10.5414/ CP203026.

33. Guglielmi V, Bel­lia A, Pecchioli S et al. Ef­fectiveness of adherence to lipid lower­­ing ther­apy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. Atherosclerosis 2017; 263: 36– 41. doi: 10.1016/ j.atherosclerosis.2017.05.018.

34. Selak V, El­ley CR, Bul­len C et al. Ef­fect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular dis­ease: randomised control­led trial in primary care. BMJ 2014; 348: g3318. doi: 10.1136/ bmj.g3318.

35. Thom S,  Poulter N, Field J et al. Ef­fects of a fix­ed--dose combination strategy on adherence and risk factors in patients with or at high risk of CVD. The UMPIRE Randomized Clinical Trial. JAMA 2013; 310(9): 918– 929. doi: 10.1001/ jama.2013.277064.

36. Planès S,  Vil­lier C,  Mal­laret M. The nocebo ef­fect of drugs. Pharmacol Res Perspect 2016;  4(2): e00208. doi: 10.1002/ prp2.208.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#